Firefly Neuroscience is a health technology startup that uses advanced artificial intelligence and signal processing to assess brain function. The company's primary offering is its Brain Network Analytics (BNA™) technology, which provides an objective assessment of cognition. This technology records brain function and compares it to an FDA-cleared, age-matched database. This comparison allows clinicians and patients to make informed decisions about therapy and disease management, and track changes over time.

Firefly Neuroscience's services are primarily targeted at clinicians, hospitals, and researchers dealing with mental illnesses and cognitive disorders. The company's technology helps these professionals understand disease progression, increase patient compliance, and assess treatment efficacy. It also aids in quicker and more conclusive diagnostic work-ups.

The company operates in the health technology market, specifically in the field of neuroscience. Its business model revolves around leveraging advances in computing to deconstruct and analyze electroencephalograms (EEGs), a test that detects electrical activity in the brain. By making these clinically useful, Firefly Neuroscience provides a valuable tool for front-line clinicians to objectively measure, monitor, and manage brain function.

In terms of revenue generation, while the company's website does not provide explicit details, it is likely that Firefly Neuroscience makes money by selling its BNA technology and related services to clinicians, hospitals, and researchers.

Keywords: Firefly Neuroscience, Brain Network Analytics, artificial intelligence, signal processing, cognition assessment, mental illnesses, cognitive disorders, EEG analysis, health technology, neuroscience.